BioMarin Files 8-K on Financial Condition and Operations

TL;DR

**BioMarin just dropped an 8-K on its financials, giving us a peek at their latest operational results.**

AI Summary

BioMarin Pharmaceutical Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing indicates that the company, incorporated in Delaware with IRS number 68-0397820, is headquartered at 770 Lindaro Street, San Rafael, California. This current report was filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Why It Matters

This filing provides an update on BioMarin's financial health and operational performance, offering transparency to investors and the market regarding its current status.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any specific new risks.

Key Players & Entities

• BioMarin Pharmaceutical Inc. (company) — Registrant
• Delaware (company) — State of incorporation
• 68-0397820 (dollar_amount) — IRS Employer Identification No.
• February 22, 2024 (date) — Date of report
• 770 Lindaro Street, San Rafael, California 94901 (company) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In

Filing Documents

• bmrn-20240222.htm (8-K) — 24KB
• earningsrelease-22feb24ex9.htm (EX-99.1) — 276KB
• bmrnlogoa01.jpg (GRAPHIC) — 4KB
• 0001048477-24-000013.txt ( ) — 454KB
• bmrn-20240222.xsd (EX-101.SCH) — 2KB
• bmrn-20240222_lab.xml (EX-101.LAB) — 24KB
• bmrn-20240222_pre.xml (EX-101.PRE) — 12KB
• bmrn-20240222_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 22, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2023. The Company's press release issued on February 22, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company dated February 22, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: February 22, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR